Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Income: 2014-2025

Historic Operating Income for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to -$45.8 million.

  • KalVista Pharmaceuticals' Operating Income rose 5.46% to -$45.8 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$171.6 million, marking a year-over-year decrease of 66.17%. This contributed to the annual value of -$188.0 million for FY2025, which is 33.86% down from last year.
  • KalVista Pharmaceuticals' Operating Income amounted to -$45.8 million in Q2 2025, which was down 3.61% from -$44.2 million recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Operating Income registered a high of -$33.2 million during Q1 2024, and its lowest value of -$48.5 million during Q2 2024.
  • For the 2-year period, KalVista Pharmaceuticals' Operating Income averaged around -$42.9 million, with its median value being -$45.0 million (2024).
  • Data for KalVista Pharmaceuticals' Operating Income shows a peak YoY climbed of 5.46% (in 2025) over the last 5 years.
  • KalVista Pharmaceuticals' Operating Income (Quarterly) stood at -$44.2 million in 2024, then climbed by 5.46% to -$45.8 million in 2025.
  • Its last three reported values are -$45.8 million in Q2 2025, -$44.2 million for Q3 2024, and -$48.5 million during Q2 2024.